TY - JOUR
T1 - Liraglutide: A molecule for treatment of type II diabetes mellitus
AU - Patel, D.S.
AU - Mehta, H.R.
AU - Ramani, A.K.
AU - Labana, P.G.
AU - Shah, S.K.
AU - Srivstava, A.K.
AU - Pathak, Y.K.
AU - Rajesh, V.
AU - Deshpande, S.
N1 - Cited By :1
Export Date: 10 November 2017
Correspondence Address: Patel, D.S.; Torrent Pharmaceuticals Limited, Torrent Research Centre, Village Bhat, District - Gandhinagar - 382428, Gujarat, India; email: devangrx@gmail.com
Chemicals/CAS: exendin 4, 141732-76-5, 141758-74-9; glimepiride, 93479-97-1; glucagon like peptide 1, 89750-14-1; insulin, 9004-10-8; insulin glargine, 160337-95-1; liraglutide, 204656-20-2; metformin, 1115-70-4, 657-24-9; rosiglitazone, 122320-73-4, 155141-29-0; tetrahydrolipstatin, 96829-58-2
Manufacturers: Novo Nordisk
References: Sobel, B.E., Schneider, D.J., (2005) Curr Opin Pharmacol, 5, pp. 143-148; Reimann, M., Bonifacio, E., Solimena, M., Schwarz, P.E.H., Ludwig, B., Hanefeld, M., Bornstein, S.R., (2009) Pharmacol Ther, 121, pp. 317-331; Jain, S., Saraf, S., (2008) Diabetes Metab Syndr. Clin Research & Review, , doi:10.1016/j.dsx.2008.04.011; Virally, M., Blickl, J.F., Girard, J., Halimi, S., Simon, D., Guillausseau, P.J., (2007) Diabetes and Metabol, 33, pp. 231-244; Hinnen, D., Nielsen, L.L., Waninger, A., Kushner, P., (2006) JABFM, 19, pp. 612-620; Leahy, J.L., (2005) Arch Med Res, 36, pp. 197-209; Palumbo, P.J., (1998) J Diabetes Complications, 12, pp. 110-119; Panunti, B., Jawa, A.A., Fonseca, V.A., (2004) Drug Discovery Today: Disease Mech/Metabol Disease, 1, pp. 151-157; Tahrani, A.A., Piya, M.K., Barnett, A.H., (2009) Adv Therap, 26, pp. 249-262; Munro, N.M., Levy, J.C., (2007) Prim Care Diabetes, 1, pp. 103-105; Ahren, B., (2007) Best practice and research: Clin Endocrinol and Metabol, 21, pp. 517-533; Holst, J.J., Deacon, C.F., (2004) Curr Opin Pharmacol, 4, pp. 589-596; Rossi, M.C., Nicolucci, A., (2009) Acta Biomed, 80, pp. 93-101; (2009), Novo Nordisk's diabetes drug liraglutide (Victoza) FDA approval delayed in US, December 30; Russel-Jones, D., (2009) Mol Cellular Endocrinology, 297, pp. 137-140; Deacon, C.F., (2009) Vasc Health Risk Manag, 5, pp. 199-211; Feinglos, M.N., Saad, M.F., Pi-Sunyert, F.X., An, B., Santiago, O., (2005) Diabet Med, 22, pp. 1016-1023; Neumiller, J.J., Campbell, R.K., (2009) Ann Pharmacother, 43, pp. 1433-1444; Degn, K.B., Juhl, C.B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Schmitz, O., (2004) Diabetes, 5, pp. 1187-1194; Harder, H., Thi, T.D.T., Nielsen, L., Astrup, A., (2004) Diabetes Care, 27, pp. 1915-1921; Madsbad, S., Schmitz, O., Ranstam, J., Jakobsen, G., Matthews, D.R., (2004) Diabetes Care, 27, pp. 1335-1342; Vilsbol, T., Zdravkovic, M., Le-thi, T., Krarup, T., Schmitz, O., Courreges, J.P., Verhoeven, R., Madsbad, S., (2007) Diabetes Care, 30, pp. 1608-1610; Seino, Y., Rasmussen, M.F., Zdravkovic, M., Kaku, K., (2008) Diabetes Res Clin Pract, 81, pp. 161-168; Marre, M., Shaw, J., Brändle, M., Bebakar, W.M.W., Kamaruddin, N.A., Strand, J., Zdravkovic, M., Colagiuri, S., (2009) Diabet Med, 26, pp. 268-278; Garber, A., Henry, R., (2009) Lancet, 373, pp. 473-481; Zinman, B., Gerich, J., Buse, J.B., Lewin, A., Schwartz, S., Raskin, P., Hale, P.M., Blonde, L., (2009) Diabetes Care, 32, pp. 1224-1230; Buse, J.B., Rosenstock, J., (2009) Lancet, 374, pp. 39-47
PY - 2010
Y1 - 2010
N2 - Type 2 diabetes mellitus is a common chronic disease that causes significant morbidity and mortality worldwide. Currently available antidiabetic agents work by different mechanisms to lower blood glucose levels. Available treatments (such as metformin, sulfonylureas, glitazones, and insulin) have proven unsatisfactory in producing a long-lasting impact on glycemic control. In addition, most of these treatments have undesirable side effects such as weight gain and hypoglycemia. As a result, exploring new treatment targets and new therapies is mandatory in order to treat this condition. The incretin pathway, in particular glucagon-like peptide (GLP-1), plays an important pathological role in the development of T2DM, and treatments targeting the incretin system have recently become available. The actions of GLP-1 include (a) a stimulation of insulin secretion in a glucose-dependent manner, (b) a suppression of glucagon, (c) a reduction in appetite and food intake, (d) a deceleration of gastric emptying, (e) a stimulation of ß-cell neogenesis, growth and differentiation in animal and tissue culture experiments. Intravenous GLP-1 can normalize and subcutaneous GLP-1 can significantly lower plasma glucose in the majority of patients with Type 2 diabetes. Current data suggest that liraglutide significant reductions in fasting and postprandial plasma glucose and hemoglobin A1c (HbA1c). Liraglutide is well tolerated and does not increase hypoglycemia. Liraglutide, a GLP-1 analog, offers a novel treatment option for patients with type 2 diabetes mellitus.
AB - Type 2 diabetes mellitus is a common chronic disease that causes significant morbidity and mortality worldwide. Currently available antidiabetic agents work by different mechanisms to lower blood glucose levels. Available treatments (such as metformin, sulfonylureas, glitazones, and insulin) have proven unsatisfactory in producing a long-lasting impact on glycemic control. In addition, most of these treatments have undesirable side effects such as weight gain and hypoglycemia. As a result, exploring new treatment targets and new therapies is mandatory in order to treat this condition. The incretin pathway, in particular glucagon-like peptide (GLP-1), plays an important pathological role in the development of T2DM, and treatments targeting the incretin system have recently become available. The actions of GLP-1 include (a) a stimulation of insulin secretion in a glucose-dependent manner, (b) a suppression of glucagon, (c) a reduction in appetite and food intake, (d) a deceleration of gastric emptying, (e) a stimulation of ß-cell neogenesis, growth and differentiation in animal and tissue culture experiments. Intravenous GLP-1 can normalize and subcutaneous GLP-1 can significantly lower plasma glucose in the majority of patients with Type 2 diabetes. Current data suggest that liraglutide significant reductions in fasting and postprandial plasma glucose and hemoglobin A1c (HbA1c). Liraglutide is well tolerated and does not increase hypoglycemia. Liraglutide, a GLP-1 analog, offers a novel treatment option for patients with type 2 diabetes mellitus.
M3 - Article
SN - 0975-8585
VL - 1
SP - 193
EP - 201
JO - Research Journal of Pharmaceutical, Biological and Chemical Sciences
JF - Research Journal of Pharmaceutical, Biological and Chemical Sciences
IS - 2
ER -
